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Selective Inhibition of ADAM17 Efficiently Mediates
Glycoprotein Iba Retention During Ex Vivo
Generation of Human Induced Pluripotent Stem
Cell-Derived Platelets
SHINJI HIRATA,a,b TAKAHIKO MURATA,b DAISUKE SUZUKI,a SOU NAKAMURA,a RYOKO JONO-OHNISHI,a
HIDENORI HIROSE,a,c AKIRA SAWAGUCHI,d SATOSHI NISHIMURA,e NAOSHI SUGIMOTO,a KOJI ETOa,f
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ABSTRACT
Donor-independent platelet concentrates for transfusion can be produced in vitro from induced plu-
ripotent stem cells (iPSCs). However, culture at 37°C induces ectodomain shedding on platelets of gly-
coprotein Iba (GPIba), the von Willebrand factor receptor critical for adhesive function and platelet
lifetime in vivo, through temperature-dependent activation of a disintegrin andmetalloproteinase 17
(ADAM17). Theshedding canbesuppressedbyusing inhibitorsofpanmetalloproteinases andpossibly
of the upstream regulator p38 mitogen-activated protein kinase (p38 MAPK), but residues of these
inhibitors in the final platelet productsmay be accompanied by harmful risks that prevent clinical ap-
plication. Here,weoptimized the culture conditions for generating human iPSC-derivedGPIba+ plate-
lets, focusing on culture temperature and additives, by comparing a new and safe selective ADAM17
inhibitor, KP-457,with previous inhibitors. Because cultivation at 24°C (atwhich conventional platelet
concentrates are stored) markedly diminished the yield of platelets with high expression of platelet
receptors, 37°Cwas requisite for normal platelet production from iPSCs. KP-457 blocked GPIba shed-
ding from iPSC platelets at a lower half-maximal inhibitory concentration than panmetalloproteinase
inhibitor GM-6001, whereas p38MAPK inhibitors did not. iPSC platelets generated in the presence of
KP-457 exhibited improved GPIba-dependent aggregation not inferior to human fresh platelets. A
thrombus formationmodel using immunodeficient mice after platelet transfusion revealed that iPSC
platelets generatedwith KP-457 exerted better hemostatic function in vivo. Our findings suggest that
KP-457, unlike GM-6001 or p38 MAPK inhibitors, effectively enhances the production of functional
human iPSC-derived platelets at 37°C, which is an important step toward their clinical applica-
tion. STEM CELLS TRANSLATIONALMEDICINE 2016;5:1–11
SIGNIFICANCE
This study is a tip for overcoming a practical but critical barrier for manufacturing human induced
pluripotent stem cell (iPSC) platelets for clinical use. Unavoidable cleavage of glycoprotein Iba dur-
ing manufacturing at 37°C was completely blocked using KP-457, a safe and selective ADAM 17
(a disintegrin andmetalloproteinase 17 inhibitor), which enabled the platelets to exert improved he-
mostatic function in vivo. The strategy contributes to the realization of the clinical application of
iPSC-derived platelets.
INTRODUCTION
Platelet transfusion is essential for the treatment of
thrombocytopeniaassociatedwithhematologicdis-
eases, trauma,andcancerchemotherapy.However,
platelet concentrates have a short shelf life and, at
present, canbesuppliedonly fromblooddonations,
which have associated risks of bacterial and viral
infection. In addition, there are unmet needs for
platelets expressing specific human leukocyte anti-
gens or human platelet antigens. Human induced
pluripotent stem cells (iPSCs) [1], which are avail-
able from diverse donors, could represent a potent
new source of platelets that solves these problems.
For this reason, we and others have recently devel-
oped an in vitro culture method whereby platelet-
producing megakaryocytes (MKs) are generated
from human embryonic stem cells (ESCs) or iPSCs
[2–6]. However, because one-shot platelet transfu-
sion requires more than 2–3 3 1011 platelets in a
200-ml package, improvements in the efficiency
of ex vivo platelet manufacturing are needed.
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Donated platelets are stored at room temperature (20–24°C)
to avoid a gradual loss of quality (i.e., platelet storage lesion) [7].
Stored platelets are subject to losing the extracellular domain of
glycoprotein Iba (GPIba), which is enzymatically cleaved by a dis-
integrin andmetalloproteinase 17 (ADAM17) (tumornecrosis fac-
tor [TNF]-a converting enzyme) [8]. GPIba is the receptor subunit
of the GPIb/GPIX/GPV complex, which binds to von Willebrand
factor (vWF) and enables platelets to attach to injured blood ves-
sels under high shear stress. Without intact GPIba, platelets lose
the ability to properly attach to the vessel wall and thus become
dysfunctional [8–10]. In addition, plateletswithoutGPIbaarealso
rapidly cleared after transfusion [9, 10], indicating that high GPIba
expression is a critical factor to determine the lifetime of circulating
platelets in vivo.
We previously demonstrated that the functionality of
GPIba+ iPSC-derived platelets is intact and able to circulate
and contribute to hemostasis in vivo [5], but GPIba shedding
also occurs during in vitro platelet generation from mouse or
human ESCs/iPSCs [4, 5, 10]. We therefore examined different
approaches to inhibit this phenomenon. Because donated
platelets are stored at 24°C to inhibit GPIba shedding, we
assessed the effect of reducing the cultivation temperature
used during the generation of iPSCs-derived cells to 24°C. In ad-
dition, we examined the effect of pharmacologically inhibiting
ADAM17 in cultures at 37°C. Panmetalloproteinase inhibitors
with a hydroxamate structure, such as GM-6001, have been
used to inhibit GPIba shedding during the storage of donated
platelets and cultivated iPSC platelets [5, 9, 10]. In addition,
p38 mitogen-activated protein kinase (p38 MAPK) is activated
during the storage of human andmouse platelets, and pharma-
cologic inhibition of p38MAPK enhanced GPIba retention, poten-
tially through suppression of ADAM17 activation [11]. However,
it is unknown whether p38 MAPK inhibition is effective at pre-
venting GPIba shedding from human iPSC-derived platelets.
In addition to these molecules, it was reported that metallopro-
teinase 8 (MMP8) inhibition during human iPSC platelet gener-
ation may prevent platelets from shedding GPIba [2], although
the contribution to shedding made by MMP8 has not been fully
clarified. It thus remains unknown which molecule or combina-
tion of them is most effective at maximizing GPIba retention
during the generation of human iPSC platelets. In addition, to
consider the final platelet product from culture media, safety
concerns associated with components in the platelet transfu-
sion package should be identified. Unfortunately, the safety
of GM-6001 and MMP8 inhibitor I (M8I) has never been deter-
mined, whichmay be an obstacle to the realization of clinical ap-
plication because of potential risks of unexpected adverse
health events in clinical use. In the present study, we show that
the selective inhibition of ADAM17 using a novel selective and
safe ADAM17 inhibitor, KP-457, but not p38 MAPK, is effective
for generating functional platelets from iPSCs.
MATERIALS AND METHODS
Cells and Reagents
All reagents were obtained from Sigma-Aldrich (St Louis, MO,
http://www.sigmaaldrich.com) unless indicated otherwise. We
used TKDA3-4, a human iPSC clone; KhES-3, a human ESC clone
(a gift from Dr. H. Suemori, Institute for Frontier Medical Sci-
ences, Kyoto University, Kyoto, Japan); and an immortalized
megakaryocyte progenitor cell line (imMKCL, clone 7), which
was previously established from iPSC-derived hematopoietic
progenitor cells (HPCs) [5, 12]. ThemouseC3H10T1/2 feeder cell
line was from the Riken BioResource Center (Tsukuba, Ibaraki,
Japan, http://en.brc.riken.jp) [4, 5, 13]. Control human platelets
were prepared from blood collected after obtaining signed in-
formed consent from the donors and approval from the Ethical
Committee of the Institute of Medical Science at the University
of Tokyo (approval no. 22-17-0804). All studies involving the use
of human samples were conducted in accordance with the Dec-
laration of Helsinki.
The following antibodies were obtained from BD (Franklin
Lakes, NJ, http://www.bd.com) unless indicated otherwise:
allophycocyanin (APC)-conjugated anti-CD41a (integrin aIIb/b3
complex), eFluor450-conjugated anti-CD42a (GPIX) (eBioscience,
San Diego, CA, http://www.ebioscience.com), phycoerythrin-
conjugated anti-CD42b (GPIba), V450, and APC-conjugated
anti-CD9. A novel selective ADAM17 inhibitor with a reverse-
hydroxamate structure, KP-457 [N-(2-{[4-(but-2-yn-1-yloxy)
phenyl]sulfonyl}-1-[4-(methylsulfonamidomethyl)phenyl]ethyl)-
N-hydroxyformamide], was supplied by Kaken Pharmaceutical
Co., Ltd. (Tokyo, Japan). The panmetalloproteinase inhibitor
GM-6001, p38 MAPK inhibitor SB203580, MAPK/extracellular
signal-regulated kinase kinase (MEK) inhibitor U0126, IkB kinase
b (IKKb) inhibitor BMS345541, caspase inhibitor Z-VAD, and pro-
tein kinase C (PKC) inhibitor Ro31-8220were from EMDMillipore
(Billerica,MA, http://www.emdmillipore.com). Thep38MAPK in-
hibitor BIRB796 was from Axon Medchem (Groningen, Nether-
lands, https://www.axonmedchem.com). Human plasma was
prepared by centrifugation from whole blood containing 10%
acid citrate dextran, after which the supernatant was filtered
through a 0.22-mm filter (EMD Millipore).
Hematopoietic Differentiation of Human iPSCs and ESCs
Directed differentiation toMKs and platelets from iPSCs and ESCs
was performed as described previously [5, 13]. Briefly, 3 3 104
HPCs derived from iPS-sacs on C3H10T1/2 feeder cells in the pres-
ence of 20 ng/ml vascular endothelial growth factor were trans-
ferred on day 14 of culture onto C3H10T1/2 feeder cells in
differentiation medium supplemented with 50 ng/ml stem cell
factor, 100 ng/ml thrombopoietin, 25 U/ml heparin sodium,
and test compounds at 24°C or 37°C. The medium was refreshed
every 3 days, and nonadherent cells were collected and analyzed
on days 22–24.
Expansion of imMKCLs and Platelet Production
imMKCL expansion and subsequent platelet production were per-
formed as previously reported [12]. Briefly, imMKCLs were cul-
tured in the presence of doxycycline for self-replication by the
expression of three doxycycline-regulated transgenes: c-MYC,
BMI1, andBCL-XL. imMKCLswere subsequently cultured for 5 days
in the absence of doxycycline to produce platelets by turning the
transgenes off, with or without 15 mmol/l KP-457.
Flow Cytometric Analysis of In Vitro Differentiated MKs
and Platelets
Flow cytometric analysis was performed as previously described
[4, 5, 12, 13]. Briefly, iPSC- and ESC-derived MKs on days 22–24
and platelets in their supernatants were stained with combina-
tions of antibodies for 30minutes on ice (forMKs) or at room tem-
perature (for platelets). Samples of MKs/platelets were then
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washed, diluted with staining medium (phosphate-buffered sa-
line containing 3% fetal bovine serum), and analyzed using flow
cytometry (FACSAria; BD). Trucount tubes (BD) were used to
quantify the MKs and platelets.
Carbonyl Cyanide m-Chlorophenylhydrazone-Induced
GPIba Shedding From Washed Platelets
Washedplateletswerepreparedasdescribedelsewhere [5]. Platelets
suspended in Tyrode-HEPES buffer (1.5–2.5 3 108 cells/ml) were
treatedwith 100mmol/l carbonyl cyanidem-chlorophenylhydrazone
(CCCP) at 37°C overnight in the absence or presence of inhibitors
before further analysis.
Flow Cytometry-Based Platelet Aggregation Assay
Flow cytometry platelet aggregation assays were performed as
recently described [12, 14]. Aliquots of iPSC platelets, imMKCL
platelets, or fresh washed human platelets were stained with
anti-CD9-APC or anti-CD9-V450, and CD41a+ platelets were
counted using flow cytometry. Next, aliquots of platelets stained
using anti-CD9-APC were mixed with platelets stained using anti-
CD9-V450 at a 1:1 ratio (1–43105 cells/ml each) and suspended
in Tyrode-HEPES solution containing 20 mmol/l PPACK (a throm-
bin inhibitor), 10% filtered human plasma, and 3 mmol/l CaCl2.
The mixed platelets were stimulated with 2 mg/ml ristocetin
or 100 mmol/l TRAP6 and 50 mmol/l ADP for 10 minutes at
37°C while swirling, fixed, and analyzed using flow cytometry.
To quantify platelet aggregation, an index of double-colored
events (%) was calculated using the following formula described
elsewhere [14]:
Double-colored events (%)
= [APC+V450+/(APC+V450+ + APC+V4502 + APC2V450+)]3 100
MMP and ADAM Activity Assays
KP-457 andGM-6001were tested for their ability to inhibitMMP-
and ADAM-catalyzed cleavage of substrates in a fluorescence-
based assay. Human ADAM17, ADAM10, and MMP17 were from
R&D Systems (Minneapolis, MN, http://www.rndsystems.com),
and human MMP1, MMP2, MMP3, MMP8, MMP9, MMP13, and
MMP14 were from EMDMillipore. MMP1, MMP2, MMP8, MMP9,
MMP13, and MMP17 were activated using p-aminophenylmercuric
acetate (Sigma-Aldrich) before testing. Fluorogenic substrates for
measuring activity of ADAM10 and ADAM17 [Nma-LAQAVRSSK
(Dnp)r-NH2, based on the cleavage site of TNF-a]; MMP1, MMP9,
MMP13, and MMP14 [Dnp-P-Cha-GC(Me)HAK(N-Me-Abz)-NH2];
MMP3 [MOCAc-RPKPVE-Nva-WRK(Dnp)-NH2]; and MMP2, MMP8,
and MMP17 [MOCAc-PLGL-A2pr(Dnp)-AR-NH2] were all provided
by Peptide Institute (Osaka, Japan, https://www.peptide.co.jp/
en) and used as substrates. In addition, inhibitory activities were
measured using LC/MS/MS with a GPIba-based substrate peptide
(KKTIPELDQPPKLRGVLQGHLESSRNDPFLHPDF), a C terminal-based
standard peptide (VLQGHLESSRNDPFLHPDF), and an internal
standard peptide (VTTGKGQDHSPFWGF). These peptides were
synthetized by Scrum (Tokyo, Japan, http://www.scrum-net.co.
jp/english/top_en.htm).
Transmission Electron Microscopy Analysis
Transmissionelectronmicroscopy (TEM)wasperformedasdescribed
previously [12]. Samples were observed using a transmission
electron microscope operating at 80 kV (HT-7700; Hitachi,
Tokyo, Japan, http://www.hitachi.com).
Immunostaining and Confocal Microscopy Analysis
Confocalmicroscopywas performedas describedpreviously [12].
All observations were made using an A1 confocal microscopic
system (Nikon, Tokyo, Japan, http://www.nikon.com) equipped
with an 363/1.40 numerical aperture oil-immersion objective.
imMKCL-derived platelets were attached on fibrinogen-coated
cover glass. For activation, platelets were treated with 200 mmol/l
ADP and 40 mmol/l TRAP6. The cells were fixed, permeabilized,
and stained with anti-b1-tubulin antibody (1:1,000; Medical &
Biological Laboratories, Nagoya, Japan, http://www.mbl.co.
jp), for detecting microtubule coils in resting platelets, or with
rhodamine-phalloidin (1:500; Thermo Fisher Scientific Life Sci-
ences, Waltham, MA, http://www.thermofisher.com) and anti-
CD41a antibody (1:100; eBioscience), for detecting spreading
F-actin fibers in activated platelets. Alexa Fluor 488-conjugated
secondary antibody (1:500; Thermo Fisher) was also used.
Clot Retraction Assay
Clot retraction assays were carried out as previously reported
[12]. In brief, imMKCL platelets suspended in 20% platelet-
depleted plasma containing Iscove’s modified Dulbecco’s me-
dium (3.6 3 108 cells/ml) in the presence of thrombin (2 U/ml)
were incubated at 37°C for 2 hours to induce clot formation
and retraction.
In Vivo Imaging for Thrombus Formation by
iPSC platelets
The procedure was identical to that in the previous report [5, 12].
Small vessels (,25mm in diameter) withinmesenteric capillaries
of male NOD/SCID/IL-2Rg-null (NOG) mice were evaluated. NOG
mice were purchased from the Central Institute for Experimental




observed differences was determined using Student’s two-tailed
t test for pairwise comparisons orDunnett’s test formultiple com-
parisons. Significanceof cell numberswas testedafter logarithmic
transformation. Values of p, .05 were considered significant.
RESULTS
Culture at 37°C Is Critical for Efficient Generation ofMKs
and Platelets Exhibiting Good GP Retention
To remain functional, ex vivo plateletsmust bemaintainedwithin
a strict temperature window of 20–24°C. By contrast, it is com-
monly thought that iPSCs must be cultured at 37°C, but at that
temperature, platelets undergo GPIba shedding, perhaps as a re-
sult of metalloproteinase activation [10]. To assess the effect of
reducing the ambient temperature to 24°C on iPSC platelet gen-
eration, we compared platelet yields andGPIIb (CD41a)/IIIa, GPIX
(CD42a), and GPIba (CD42b) levels after incubating the cells at
24°C or 37°C during theMK differentiation phase (days 14–20) or
the platelet production phase (days 20–24) (Fig. 1A). Incubation
at 24°C during days 14–24 resulted in the reduced yield of CD41a+
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MKs from iPSC HPCs (Fig. 1B). Consistent with the reduction of
MKs, platelet biogenesis based on the CD41a+, CD41a+GPIX+,
and CD41a+GPIba+ phenotypes was also diminished at 24°C
(Fig. 1C). Likewise, the levels of individual glycoproteins were
decreased (supplemental online Fig. 1), and the numbers of
CD41a+GPIba+ platelets were much lower than those of
CD41a+GPIX+ platelets, even at 24°C (Fig. 1C). This fact is illus-
trated by the increase of platelets with theGPIbalowGPIXhigh pheno-
type, which may be associated with the changes in cell metabolism
or the shedding of GPIba at 24°C (supplemental online Fig. 1A).
These results demonstrate that cultivation at 37°C is requisite for
normal platelet production.
Inhibition of ADAM17 Using KP-457 Is Sufficient to
Retain GPIba in CCCP-Treated Aged Human Platelets
Nonspecificmetalloproteinase inhibitors [9] andp38MAPK inhib-
itors [11] are both known to inhibit GPIba shedding from human
platelets. In iPSC platelets, the metalloproteinase inhibitor GM-
6001 and MMP8 inhibitor M8I both reportedly inhibit GPIba shed-
ding [2, 5, 10]. Unfortunately,M8I is not specific forMMP8 [15]. Like
GM-6001,M8Iactsasapan-MMP/hydroxamate-based inhibitorand
thus potently inhibits ADAM17 [16].We therefore developed a
novel and selective ADAM17 inhibitor, KP-457, that has a
reverse-hydroxamate structure and assessed its effects (Fig. 2A).
ADAM17, alsoknownasTNF-a-convertingenzyme, cleaves various
molecules such as GPIba, GPV, and TNF-a [17]. In cell-free enzyme
assays, KP-457 inhibited cleavages of the TNF-a sequence with 10
times the potency of GM-6001 (Fig. 2B) and was.50 times more
selective for ADAM17 than for other MMPs and ADAM10
(Table1). In addition, we confirmed that the inhibition of
C-terminal cleavage of the GPIba sequence by ADAM17 was con-
centration dependent, with a half-maximal inhibitory concen-
tration (IC50) of 10.6 nmol/l, whereas the IC50 for GM-6001
was 53.8 nmol/l (supplemental online Fig. 2). KP-457 at the
Figure 1. Cultivation at 37°C was necessary for efficient megakaryopoiesis and thrombopoiesis of human iPSC-derived HPCs. (A): Schematic
diagram of the in vitro differentiation protocol. To generate CD41a+ MKs and CD41a+ GPIX (CD42a)+ GPIba (CD42b)+ platelets, human iPS-sac-
derived HPCs were incubated with SCF, TPO, and heparin on C3H10T1/2 feeder cells at 24°C or 37°C during the MK differentiation phase (days
14–20) and platelet production phase (days 20–24). The numbers of MKs (B) and platelets (C) derived from iPSCs were measured under the
different temperature conditions. p,p, .05 vs. 37°C culture condition on days 14–24 byDunnett’s test, n $ 3. Abbreviations: GP, glycoprotein;
HPC, hematopoietic progenitor cell; iPS, induced pluripotent stem; iPSC, induced pluripotent stem cell; MK, megakaryocyte; SCF, stem cell fac-
tor; TPO, thrombopoietin, VEGF, vascular endothelial growth factor.
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lower concentration blocks Zn2+ chelation of the catalytic domain
of ADAM17. Good laboratory practice studies confirmed that KP-
457 exhibited neither genotoxicity nor systemic toxicity at doses
up to 3 mg/kg administered to dogs intravenously once a day for
4 weeks, which was the maximal dose tested (data not shown).
CCCP induces the cleavage of GPIba in association with
mitochondrial injury, and this effect can be blocked using
GM-6001 or a p38MAPK inhibitor [9, 11]. Likewise, KP-457 sus-
tained intact GPIba at levels seen in platelets freshly isolated
from human blood (Fig. 2C, 2D). As in the cell-independent
(cell-free) enzyme activity assays, KP-457 inhibited GPIba
shedding with a potency 10 times that of GM-6001 in the
cellular assay (Fig. 2D), which is consistent with its afore-
mentioned selective inhibition of ADAM17 activity (Fig. 2B;
Table 1). These findings suggest that ADAM17 dominantly con-
trols CCCP-induced GPIba shedding from human platelets. On
the other hand, the inhibitory effects of the p38 MAPK inhib-
itors SB203580 and BIRB796 plateaued at a level around half
themaximum inhibition elicited by KP-457 or GM-6001, which
implies that ADAM17 is activated in part via a mediator other
Figure 2. CCCP-induced GPIba shedding was completely blocked by the ADAM17 inhibitor KP-457 but not by p38 MAPK inhibitors. (A):
Structure of KP-457. (B): Inhibitory effects of KP-457 and GM-6001 on ADAM17 enzymatic activity under cell-free conditions. n = 3. (C):
Representative FACS dot plots showing the inhibitory effect of KP-457 (15 mmol/l) and BIRB796 (10 mmol/l) on CCCP-induced GPIba
shedding from human washed platelets. Washed platelets were incubated with 100 mmol/l CCCP in the presence of inhibitors for
24 hours at 37°C. The GPIba+ fraction among CD41a+ platelets was measured. (D): Dose-dependent effects of the indicated inhibitors
on GPIba retention by platelets treated with CCCP. n $ 3. Abbreviations: ADAM, a disintegrin and metalloproteinase; CCCP, carbonyl
cyanide m-chlorophenylhydrazone; FACS, fluorescence-activated cell sorting; GP, glycoprotein; MAPK, mitogen-activated protein
kinase.
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than p38 MAPK. We also confirmed that KP-457 has no ad-
verse effects on platelet aggregation induced by thrombin
or collagen, whereas SB203580 and BIRB796 both diminished
collagen-induced platelet aggregation (supplemental online
Fig. 3), as reported elsewhere [18].
KP-457, but not p38 MAPK Inhibitors, Retains the
Expression of GPIba on iPSC-Derived Platelets
Wenext examined the ability of KP-457 to inhibit GPIba shedding
during the generation of iPSCplatelets in vitro. KP-457 (15mmol/l),
GM-6001 (50 mmol/l), or a p38 MAP kinase inhibitor (10 mmol/l)
was administered during the MK differentiation and platelet pro-
duction phases of HPCs cultivated at 37°C.
KP-457orGM-6001hadno significant effect on thenumberof
MKs (Fig. 3A) or CD41a+ total platelets (Fig. 3B). Importantly,
these inhibitors were able to retain the expressions of GPIba
on CD41a+ platelets (Fig. 3C, 3D). GPIba retention by KP-457
was consistently observed in platelets derived from human ESCs
(supplemental online Fig. 4A) and imMKCLs [12] (supplemental
online Fig. 4B).
On the other hand, BIRB796 and SB203580 increased MK
numbers (Fig. 3A). This increase may be attributable to an in-
creased expansion of CD34+ HPCs related to the p38 MAPK inhi-
bition [19]. As a result, the number of CD41a+ total platelets was
increased (Fig. 3B). The inhibition of p38MAPKapparently did not
affect platelet release fromMKs. Unfortunately, p38MAPK inhib-
itors failed to preserve GPIba in iPSC-derived platelets (Fig. 3C,
3D). This result suggests that p38 MAPK inhibition promotes
megakaryopoiesis but has no effect on GPIba shedding from
iPSC-derived platelets.
Because bothmetalloproteinase inhibitors and p38MAPK in-
hibitors increase the number of GPIba+ iPSC platelets, the former
by increasing the ratio of the GPIba+ population and the latter by
increasing the total number of platelets, we sought to evaluate
whether the simultaneous addition of these inhibitors could fur-
ther increase the number of GPIba+ iPSC platelets. In combina-
tion, KP-457 and BIRB796 exhibited an additive effect on the
GPIba+ platelet yield, but not on the percentage of the GPIba+
population (Fig. 4), which is consistent with our observations that
these two inhibitors contribute to an increase in GPIba+ iPSC
platelets through separate mechanisms of action.
Direct Inhibition of ADAM17 Is the Most Effective
Strategy for Retaining GPIba During iPSC
Platelet Generation
Although p38 MAPK is a putative upstream signaling molecule
contributing to ADAM17 activation during platelet preservation
[11], our results indicate it has no involvement in GPIba shed-
ding during iPSC platelet generation. To clarify the mechanism
by which ADAM17 is activated during iPSC platelet generation,
we tested the effects of inhibiting other putative upstream
molecules, including MEK1/2, IKKb, caspases, and PKCs [17,
20], all of which have been implicated in the activation of
ADAM17. The respective inhibitors were administered for the fi-
nal 2–3 days of culture, because some of them suppressed differ-
entiation to MKs and thrombopoiesis (data not shown). None of
the tested inhibitors other than KP-457 prevented the loss of
GPIba (Fig. 5).We therefore concluded that selective anddirect in-
hibition of ADAM17 is the most effective strategy for retaining
GPIba during iPSC platelet generation.
GPIba-Retaining Platelets Generated Using KP-457
Exhibited Improved Hemostatic Function In Vivo
We previously demonstrated that directly differentiated iPSC-
derived platelets or imMKCL-derived platelets exhibit platelet-
like phenotypes, including granule contents inside the cell bodies,
platelet agonist-responsive activations, circulation in blood-
stream, and contribution to hemostasis in vivo [5, 12]. Treatment
with KP-457 seemingly improved or enhanced the structural
properties of normal platelets according to TEM (Fig. 6A), micro-
tubule coil formation detected byb1-tubulin staining (supplemental
online Fig. 5A), actin reorganization via outside-in signaling
(supplemental online Fig. 5B), aggregation (supplemental online
Fig. 5C, 5D), and clot formation (supplemental online Fig. 5E).
To further examine the functionality of the GPIba-retaining
iPSC platelets generated in the presence of KP-457 in vitro, we
used a flow cytometry-based platelet aggregation assay to assess
vWF/GPIba-dependentplatelet aggregation inducedby ristocetin
[12, 14]. Upon the stimulation of a mixture of equal densities of
APC-labeled and V450-labeled platelets, a double-positive pop-
ulation was increased, and single-positive populations were
conversely decreased, with platelet aggregation.We found that
iPSC platelets generated in the presence of KP-457 exhibited
greater aggregation capability than those generated in its ab-
sence and that this capability resembled that of peripheral
blood-derived fresh platelets (Fig. 6B). Next, we examined over-
all hemostatic function in vivo by the iPSC platelets. The plate-
lets were transfused into immunodeficient NOG mice with
irradiation-induced thrombocytopenia and monitored using
an in vivo imaging system [5, 12, 21]. When equal numbers
(1 3 107 cells) of tetramethylrhodamine-labeled CD41a+ iPSC
platelets generated with or without KP-457 were transfused into
the mice before laser/reactive oxygen species-induced vessel in-
jury, a higher number of iPSC platelets contributed to thrombus
formation in the KP-457-treated group than in platelets without
KP-457 (Fig. 6C,6D;p= .0556).Basedonthese results,weconcluded
that KP-457 successfully protects the GPIb/GPIX/GPV complex
formation required for thrombus formation in vivo.
DISCUSSION
SurfaceGPIba expression is a critical determinant of platelet half-
life in vivo andmediates the attachment of circulating platelets to
Table 1. Inhibitory profile of the novel selective ADAM17 inhibitor KP-457
Inhibitor
IC50, nmol/l
ADAM17 ADAM10 MMP1 MMP2 MMP3 MMP8 MMP9 MMP13 MMP14 MMP17
KP-457 11.1 748 .100,000 717 9,760 2,200 5,410 930 2,140 7,100
GM-6001 163 642 11.3 1.36 79.8 0.247 0.400 0.435 2.96 5.16
Abbreviations: ADAM, a disintegrin and metalloproteinase; IC50, half-maximal inhibitory concentration; MMP, matrix metalloproteinase.
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damaged blood vessels under high shear stress [9, 10, 22]. The
level of intact GPIba on the platelet surface is controlled via
ADAM17-catalyzed shedding of the GPIba ectodomain [8, 23,
24]. Avoiding ADAM17-mediated shedding of GPIba using a non-
selective MMP inhibitor improved both posttransfusion kinetics
and hemostatic function of mouse platelets derived from
peripheral blood or mouse ESCs [8–10]. Here, we confirmed that
selectiveADAM17 inhibitionusingKP-457was similarly effective for
human ESC- and iPSC-derived platelets generated at 37°C, which
otherwise underwent GPIba shedding (Figs. 3–5; supplemental
online Fig. 4). Moreover, the cultivation at 37°C was requisite for
normal platelet production (Fig. 1; supplemental online Fig. 1). In
contrast, platelets as well as MKs created at 24°C expressed
decreased levels of glycoproteins (supplemental online Fig. 1), lead-
ing to insufficient hemostasis.
Although studieswithADAM17-deficientmicehave shown that
GPIba shedding frommouseplatelets isADAM17-dependent [8,11,
25], thedependencyonADAM17hadnotbeenconfirmed inhuman
platelets. Such confirmation is important because the substrate se-
lectivity of ADAM17 and ADAM10 can differ depending on species
and the type of activating stimuli [17, 25, 26]. The administration of
KP-457, a selective ADAM17 inhibitor, had a protective effect on
platelet GPIba levels in platelets derived from both human periph-
eral blood and iPSCs that was well correlated with ADAM17 inhibi-
tion (Fig. 2 and 3). Consistent with the importance of ADAM17
inhibition, thehumanGPIba sequencecontains aputativeADAM17
Figure 3. GPIba shedding from platelets generated in vitro from iPSC-MKs was effectively suppressed by KP-457 but not by p38 MAPK inhib-
itors. (A)Numbers of CD41a+ iPSC-derivedMKs. Human HPCswere incubated for 8–10 days in differentiationmedium supplementedwith stem
cell factor, thrombopoietin, heparin, and/or inhibitors at 37°C, followed by flow cytometric analysis. p38MAPK inhibitors increased MK yields,
whereas KP-457 and GM-6001 had only minor effects. (B) Numbers of CD41a+ iPSC platelets. (C) Representative FACS dot plots of platelets
generated from iPSC-derived HPCs in the presence of KP-457 or BIRB796. (D) Percentages of the GPIba+ population in CD41a+ platelets. Metal-
loproteinase inhibitors, including KP-457, but not p38MAPK inhibitors, enabled GPIba retention by iPSC-derived platelets. p, p, .05 vs. vehicle
group by Dunnett’s test, n $ 4. Abbreviations: FACS, fluorescence-activated cell sorting; GP, glycoprotein; HPC, hematopoietic progenitor cell;
iPSC, induced pluripotent stem cell; MAPK, mitogen-activated protein kinase; MK, megakaryocyte.
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cleavage site at V465, and ADAM17, but not ADAM10, cleaves the
GPIba-based peptide [27]. On the other hand, M8I also effectively
supports theproductionof functional iPSC-derivedplatelets [2].This
mechanism does not appear to be attributable to pureMMP8 inhi-
bition, as M8I is a panmetalloproteinase inhibitor and not selective
forMMP8 [15], indicating it couldpotently inhibitADAM17[16].We
therefore concluded that GPIba shedding from human platelets is
dependent on the activity of ADAM17 but not the activity of
ADAM10 or MMP8.
Our present findings indicate that KP-457 strongly blocks
GPIba shedding during in vitro aging of platelets derived frompe-
ripheral blood, ESCs, and iPSCs (Figs. 2–5; supplemental online
Fig. 4) without affecting other platelet phenotypes; e.g., forma-
tion of microtubule coils, outside-in signaling, platelet aggre-
gation, and clot formation (supplemental online Figs. 3, 5).
Interestingly, KP-457 administration improved platelet struc-
ture according to TEM (Fig. 6A). Moreover, upon ristocetin
stimulation, iPSCplatelets prepared in thepresenceof KP-457dis-
play an improved response to ristocetin that is not inferior to that
of peripheral blood platelets (Fig. 6B). More important, iPSC
platelets generated with KP-457 successfully participated in he-
mostasis in vivo (Fig. 6C, 6D), which implies that the functionality
of GPIb/IX/V complexes is sustained by KP-457.
In contrast to KP-457, p38 MAPK inhibitors did not protect
GPIba on iPSC platelets (Figs. 3–5). Oxidative stress induces
p38 MAPK-dependent digestion of GPIba in human and mouse
platelets [23], and pharmacologic inhibition of p38 MAPK blocks
GPIba shedding from platelets treated with H2O2, putatively via
ADAM17 inhibition [11]. However, it has been suggested that
p38 MAPK inhibition by SB203580 suppresses thrombin-induced
GPIba shedding from mouse platelets less effectively than GM-
6001 [28]. This observation suggests that whether selective inhi-
bition of p38 MAPK is sufficient for GPIba retention may depend
on the experimental conditions.We observed that the p38MAPK
inhibitors SB203580 and BIRB796 inhibited CCCP-induced GPIba
shedding from human peripheral blood platelets to some extent
(Fig. 2C, 2D), which is consistent with earlier reports [11].
Activation of ADAM17 is tightly regulated through its expres-
sion, phosphorylation, translocation, and localization on the cell
membrane, and also through intramolecular disulfide bridge for-
mation within its extracellular domains, which are mediated via
several signaling pathways [17]. We sought to explore the signal-
ing pathways leading to ADAM17 activation during iPSC platelet
generation by blocking various intracellular mediators, with a pri-
mary focus on kinases, but unfortunately no dominant pathway
was found (Fig. 5). Meanwhile, a study that usedmouse ADAM17
without its cytoplasmic domain suggests the possibility that spe-
cific phosphorylation in the domain is not necessarily required for
ADAM17 activation [29]. Also, iPSC platelets after release from
Figure 5. Direct inhibition of ADAM17 more effectively sustained
GPIba retention by cultured iPSC-derived platelets than suppression
of potential upstream activators of ADAM17. Percentages of the
GPIba+ population in CD41a+ iPSC-derived platelets treated with
the indicated inhibitors during the platelet production phase (days
21–23 or 24). KP-457 (15 mmol/l), BIRB796 (10 mmol/l), MAPK/
extracellular signal-regulated kinase kinase inhibitor U0126 (10 mmol/l),
IKB kinase b inhibitor BMS345541 (10 mmol/l), caspase inhibitor
Z-VAD (10 mmol/l) and protein kinase C inhibitor Ro31-8220
(3mmol/l)were used. Inhibition of potential ADAM17activatormol-
ecules failed to prevent GPIba shedding evoked by cultivation at
37°C. p, p, .05 versus vehicle group by Dunnett’s test, n $ 3. Ab-
breviations: ADAM, a disintegrin and metalloproteinase; GP, glyco-
protein; iPSC, induced pluripotent stem cell.
Figure 4. Combination of KP-457 and BIRB796 exerted an additive
effect on GPIba+ platelets yields. Percentages of the GPIba+ popula-
tion in CD41a+ platelets (A) and numbers of CD41a+ GPIba+ platelets
generated from human iPSCs (B)with or without KP-457 (15 mmol/l)
and BIRB796 (10 mmol/l). p, p , .05 vs. vehicle group by Dunnett’s
test, n = 4. Abbreviations: GP, glycoprotein; HPC, hematopoietic pro-
genitor cell; iPSC, induced pluripotent stem cell.
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Figure 6. GPIba-retaining iPSC platelets generated in the presence of KP-457 exhibited an improved response to vWF in vitro and hemostatic
function in vivo. (A): Transmission electronmicrographs of imMKCL plateletsproducedwithorwithoutKP-457. Scale bar, 2mm. (B):Percentageof
double-colored events served as an aggregation index in a flow cytometry-based platelet aggregation assay usingperipheral blood-derivedplatelets
or iPSC-derived platelets generated with or without 15mmol/l KP-457. Amixture of APC- and V450-labeled platelets was stimulated using 2mg/ml
ristocetin to evoke vWF/GPIba-dependent platelet aggregation. p, p, .05 vs. without KP-457, n $ 4. (C): Representative sequential images of
GPIba+ iPSC platelets generated with KP-457 in mouse thrombus formation model. A combination of FITC-dextran (green), Hoechst33342 (blue),
and equal numbers of tetramethylrhodamine-labeled iPSC platelets (13 107 CD41a+ platelets, red) generated with or without KP-457 were trans-
fused into irradiated NOG mice. Hematoporphyrin was also administered to induce thrombus formation by chemical reaction after laser-induced
injury.Mesenteric capillaries were visualized using a confocal laser scanningmicroscope. Attachment of platelets including tetramethylrhodamine-
positive iPSC platelets on injured blood vessels and subsequent thrombus formationwere observed after the injury.White arrow, directionof blood
flow; pink arrow, site of thrombus formation. Scale bar, 10 mm. (D): The number of iPSC platelets in thrombus formation was estimated using the
images of 30 vessels from twomice of the same group in two independent experiments. GPIba-retained iPSC-derived plateletswith KP-457 exerted
more effective hemostatic function in vivo. p, p = .0556 vs. vehicle group, n = 30. Abbreviations: APC, allophycocyanin; GP, glycoprotein; imMKCL,
immortalized megakaryocyte progenitor cell line; iPSC, induced pluripotent stem cell; vWF, von Willebrand factor.
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the MKs could be continuously affected by the culture itself, i.e.,
changes in pH, temperature, and oxygen partial pressure, which
might cause ADAM17 activation through unknown kinases or cy-
toplasmic domain-independent mechanisms.
p38MAPK inhibition had no positive effect on GPIbamainte-
nance in iPSC platelets (Figs. 3C, 3D, and 4A) but increased the to-
tal numberof iPSCplatelets by increasing thenumberof iPSC-MKs
(Fig. 3A, 3B), and combination with ADAM17 inhibition additively
increased the yield of GPIba+ platelets (Fig. 4B). Inhibition of p38
MAPK using inhibitors or short hairpin RNAs (shRNAs) reportedly
affects several stages of hematopoiesis and megakaryopoiesis in
vitro, including the expansion of cord blood-derived CD34+HSPCs
[19], specification into the MK lineage, and maturation [30], which
may account for the ability of p38 MAPK inhibitors to increase the
number of iPSC-MKs during HPC culture. Were a clinically safe p38
MAPK inhibitor to become available, its combined use with KP-457
could improve the production of iPSC-derived platelets.
The present study focuses on GPIba shedding but does not
address the shedding of GPVI, a collagen receptor that regulates
platelet activation signaling [31]. Patients with GPVI defects or
compound heterozygousmutations of GPVI displaymild bleeding
[31–33]. GPVI shedding is observed during platelet generation
from mouse ESCs and is partially inhibited by the nonselective
MMP inhibitor GM-6001 at a high concentration (100 mmol/l)
[10]. GPVI shedding is suspected during in vitro human platelet
generation [12, 14]. In humans, ADAM10 is a major sheddase
of it [27]. Because KP-457 and GM-6001 had similar IC50 values
against ADAM10 (Table 1), comparable effects of KP-457 on GPVI
shedding would be expected. To further improve the function of
the platelets generated in vitro, the retention of GPVI expression
should be addressed in the next step.
For successful clinical application of iPSC technology to plate-
let transfusion, production of platelets in large quantity and high
quality is needed.We recently established an imMKCL system for
robust self-replication and platelet production [12]. The imMKCL
systemrequires5-daycultivation forplatelet production, inwhich
the platelets are released between days 3 and 5 (data not shown).
In accordance with our observation that GPIba expression on
platelets is highly maintained for 3 days in the presence of KP-
457 under static culture conditions at 37°C (data not shown),
we confirmed that KP-457 consistently facilitated the generation
of imMKCL platelets of higher quality based on GPIba expression
level (supplemental online Fig. 4B). Meanwhile, recent reports
have revealed that a new platelet storage buffer, BRS-A, which
is based on clinically available bicarbonated Ringer’s solution
(BRS) and acid-citrate-dextrose formula A, successfully maintains
human platelets, including GPIba expression, for 7 days at room
temperature [34]. Combination of KP-457 for the generation of
GPIba+ iPSC platelets at 37°C and BRS-A solution for storage at room
temperature (22–24°C)may contribute to a donor-independent iPSC
platelet supply system aimed at clinical use.
Also for the goal of clinical application, a GPIba shedding in-
hibitor that is well tolerated should be chosen. Because platelet
concentrates contain material residues when intravenously in-
jected, thematerials should be eliminated before injection if they
are toxic. However, it is not easy to purify platelets completely
without platelet activationbecauseof platelets’ inherent fragility.
Therefore, GM-6001, which needs high concentrations for its ac-
tion,may be unsuitable for clinical use. Additionally, nonselective
metalloproteinase inhibitors were reported to induce musculo-
skeletal inflammation in clinical trials, potentially because of
the broad inhibition of metalloproteinases [35]. The selective
ADAM17 inhibitor KP-457 was developed and confirmed to have
very little risk of genetic or systemic toxicities. Overall, KP-457will
be a favorable process aid for GPIba retention on platelets gen-
erated in culture, which will improve platelet quality.
CONCLUSION
Our findings indicate that the selectiveblockadeofADAM17using
KP-457 safely enables iPSC-derived platelets to retain GPIba and
thus remain functional. These effects are an important step to-
ward the realization of platelet clinical applications.
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